GlassScriptPhysician profile
Deepika Srinivasan
NPI 1811133762
$4,165.76
in general payments reported to CMS, 2019-2025
18 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $172 · 2023: $523 · 2024: $1,173 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,699 · Consulting Fee: $1,245 · Education: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,698.59 |
| Consulting Fee | $1,245.00 |
| Education | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,799.07 | 2023-2025 | Tremfya, Stelara |
| Abbvie INC. | $866.32 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $283.65 | 2023-2025 | Tremfya, Remicade, Stelara |
| Pfizer INC. | $275.17 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $141.58 | 2022-2025 | |
| Lilly USA, LLC | $134.94 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $112.35 | 2024 | Zeposia |
| Ardelyx, INC. | $108.15 | 2024-2025 | Ibsrela |
| Celgene Corporation | $93.61 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $81.51 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.46 | 2023-2025 | Xifaxan, Trulance |
| Celltrion USA INC. | $67.49 | 2024-2025 | Vegzelma |
| Ipsen Biopharmaceuticals, INC | $31.06 | 2024 | Iqirvo |
| Redhill Biopharma INC. | $27.94 | 2023 | Talicia |
| Madrigal Pharmaceuticals | $21.22 | 2024 | Resmetirom |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $18.69 | 2024 | |
| Braintree Laboratories, INC. | $17.59 | 2024 | Sutab, Suflave |
| Vivus LLC | $16.96 | 2024 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepika Srinivasan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.